NATIONAL INFLUENZA VACCINE SUMMIT

Atlanta – April 19, 2007
GSK’s Commitment to Influenza Market

Proven track record of providing influenza vaccine to global market from vaccine headquarters in Rixensart, Belgium

GSK entered US influenza market in 2004 and has invested $2 Billion

- Expanded capacity of influenza vaccines and anti-viral Relenza through acquisitions and expansions
  - Acquired ID Biomedical and Marietta, PA facility
  - North American based manufacturing - Relenza
- Received FDA approval for 2 vaccines
GSK Influenza Products, 2007/2008

Fluarix - manufactured in Dresden, Germany
- Indicated for adults 18 years of age and older
- Available in pre-filled syringes
- Trace thimerosal (<1.0 mcg per dose) as a result of manufacturing process

FluLaval - manufactured in Laval, Quebec
- Indicated for adults 18 years of age and older
- Available in multi-dose vials
- Thimerosal as a preservative (0.01% per dose)

Relenza - manufactured in Everuex, France
- Indicated for the Prophylaxis and Treatment of Influenza type A and B in ages 5 and up
- Available in a Rotadisk Inhaler
GSK Committed to the US Influenza Vaccines marketplace

GSK will continue to increase capacity in the future as needed to meet public health needs and market demand.
Distribution by account type 2006/2007 Influenza Season

Made available 25 million doses of FluLaval and Fluarix to US

- Physicians 38%
- Hosp/LTC 29%
- CIPs/Retail 14%
- Federal 11%
- Public Health 8%
- Fluarix Sold direct from GSK

Dist Primarily Through PSHs
Distribution by month
2006/2007 Influenza Season

Distribution by Month

Flulaval License
GSK 2007/2008 Distribution Plans

Provide approximately 30-35 million doses of Fluarix and FluLaval

Most Fluarix will be distributed directly by GSK
  – Gskvaccinesdirect.com

FluLaval will be sold and distributed by three distributors:
  – ASD Healthcare
  – Henry Schein
  – McKesson
GSK focused on Increasing Influenza Vaccination Rates

- Develop health care worker toolkits to assist in implementation of JCAHO recommendations
- Support programs and advocacy to increase rates of influenza vaccination among persons with chronic disease
- Participate in NFID-led influenza public relations efforts
- Support innovative influenza vaccination programs for later season vaccination
  - NACCHO demonstration projects
  - Influenza Vaccine Summit Awards
  - NIVW
Vaccines Innovation for the Future

Address unmet need in children –
  – development of a t-free pediatric influenza vaccine

Improve vaccine effectiveness through innovation
  – Novel adjuvants

Explore other delivery systems
  – Intranasal/other

Accelerate manufacturing processes
  – Cell based technology
Thank You!

GSK Vaccines
2006 National Influenza Vaccination Week Activities

Co-chair of the Summit’s “Extending the Season” workgroup
Worked across GSK sales forces (e.g., asthma, diabetes) to raise awareness about NIVW
Supported the development of www.preventinfluenza.org
Developed a holiday-themed poster with the Flu Summit